Key facts
- ALPHA CAPITAL ANSTALT filed SCHEDULE 13G/A for ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE (AIXC).
- Disclosed ownership: 0.51%.
- Date of event: 28 Jan 2026.
ALPHA CAPITAL ANSTALT - 28 Jan 2026 SCHEDULE 13G/A Report for ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE (AIXC)
- Filing manager
- ALPHA CAPITAL ANSTALT
- Reporting owner
- Alpha Capital Anstalt
- Security
- ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE
- Symbol
- AIXC
- Shares outstanding
- 7,059,412 shares
- Disclosed shares
- 36,003 shares
- Ownership percentage
- 0.51%
- Form type
- SCHEDULE 13G/A
- Filing time
- 29 Jan 2026, 16:05:27 UTC
- Event date
- 28 Jan 2026
- Previous filing
- 12 Nov 2025
- SEC filing
- View on sec.gov
Reporting parties
Subject security
Ownership signal
SEC evidence
Key filing fact
ALPHA CAPITAL ANSTALT disclosed 0.51% ownership in ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE (AIXC) on 28 Jan 2026.
Change
- Previous schedule filing date: 12 Nov 2025.
- Current filing was accepted on 29 Jan 2026, 16:05.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (1)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Alpha Capital Anstalt | 0.51% | 36,003 | 36,003 | 0 | /s/ Konrad Ackermann | Konrad Ackermann/Director |
CIK / CUSIP context first